Corrigendum to the EGM Notice dated 8th June 2026

Date: June 23, 2026 The General Manager BSE Limited, 1st Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001. BSE Scrip Code: 540359 Subject: Corrigendum to the Notice of (02/2026-27) Extraordinary General Meeting of the Shareholders of Parmax Pharma Limited to be held on 2nd July, 2026. Ref: Our earlier Intimation dated 9th June, 2026, for Notice of EGM. This is in continuation of the Notice of (02/2026-27) Extraordinary General Meeting of the Company (“EGM Notice”) dated June 8, 2026, which has already been circulated to all the shareholders of the Company on June 9, 2026. A Corrigendum is being issued today to inform all the Shareholders to whom the Notice of Extraordinary General Meeting has been sent regarding the following corrections in the EGM Notice and Explanatory Statement: (a) correction of the proposed status / category of Ms. Sheetal Hiren Doshi in the table appearing under Item No. 4 of the EGM Notice and (b) rectification of the hyperlink for the Practicing Company Secretary’s Certificate appearing in Point No. XXVII of the Explanatory Statement;. A copy of the Corrigendum to the Notice of the EGM is enclosed herewith. Except as detailed in the attached Corrigendum, all other items of the Notice of EGM, along with the Explanatory Statement dated June 8, 2026, shall remain unchanged. This Corrigendum will also be available on the Website of the Company at www.parmaxpharma.com. Please note that on and from the date hereof, the EGM Notice dated June 8, 2026 shall always be read collectively with this Corrigendum. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we kindly request you to take into record the above submissions and the attached Corrigendum. Thanking you. Yours faithfully, For Parmax Pharma Limited Umang Alkesh Gosalia Managing Director DIN: 05153830 Encl: As Above CORRIGENDUM TO THE NOTICE OF (2ND/2026-27) EXTRAORDINARY GENERAL MEETING OF PARMAX PHARMA LIMITED An Extraordinary General Meeting ("EGM") of the Members of Parmax Pharma Limited ("Company") is scheduled to be held on Thursday, July 2, 2026 at 11:30 A.M. (IST) through Video Conferencing ("VC") / other Audio-Visual Means ("OAVM"). The Notice of the EGM dated June 8, 2026 (“Notice” or “Notice of EGM”) was circulated to the shareholders of the Company on June 9, 2026 in compliance with the provisions of the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable laws. This corrigendum to the Notice of the EGM (“Corrigendum”) is being issued in continuation to the Notice together with the explanatory statement thereof and this Corrigendum shall be deemed to be an integral part of the Notice of EGM. This Corrigendum is being issued to rectify the hyperlink provided in respect of the Practicing Company Secretary's Certificate and to rectify the inadvertent typographical error in category of Warrant Allottee referred to in the Notice and Explanatory Statement relating to the Preferential Issue of Equity Shares and Convertible Warrants. The shareholders are hereby informed and take note of the following changes in the resolution Item no 4 of Notice of EGM; (a). Correction in Item No. 4 – Proposed Status / Category of Ms. Sheetal Hiren Doshi in the Warrant Allottees Table: In the table appearing under Resolution for Item No. 4 of the Notice of EGM, which sets out the details of the Proposed Warrant Allottees, the entry pertaining to Ms. Sheetal Hiren Doshi under the column “Proposed status / Category of the Allottees” have been inadvertently mentioned as “Promoter*”. The correct proposed status / category of Ms. Sheetal Hiren Doshi is to be read as “Promoter Group*” Accordingly, the Table in the Item No. 4 of Resolution shall be substituted and read as under: Type of Maximum Name of the Total Proposed status / Proposed number of Current Status / Proposed Warrant Consideration Category of the Warrant Warrants to be Category Allottees (in ₹) Allottees Allottees offered Dhiren Chandulal Individual 5,35,715 1,95,53,598 Non-Promoter Public Promoter* Shah Sunil Chinubhai Individual 81,494 29,74,531 Non-Promoter Public Promoter* Shah Hiren Pravin Doshi Individual 1,92,857 70,39,281 Non-Promoter Public Promoter* Sheetal Hiren Doshi Individual 21,429 7,82,159 Non-Promoter Public Promoter Group * Non-Promoter Public Nirmal Sunilbhai Individual 1,44,715 52,82,098 and an existing Promoter Group* Shah shareholder Dhairya Dhiren Individual 1,07,143 39,10,720 Non-Promoter Public Promoter Group* Shah Rupa Sunil Shah Individual 61,363 22,39,750 Non-Promoter Public Promoter Group* Vijaykumar Individual 1,42,857 52,14,281 Non-Promoter Public Promoter Group* Natvarlal Shiyani Non-Promoter Public Kamlesh Natvarlal Individual 1,43,286 52,29,939 and an existing Promoter Group* Shiyani shareholder Abhay Chinubhai Individual 2,85,715 1,04,28,598 Non-Promoter Public Promoter Group* Shah Urvi Manish Kothari Individual 1,42,857 52,14,281 Non-Promoter Public Public Mili Saumil Shah Individual 1,42,857 52,14,281 Non-Promoter Public Public Fredun Nariman Individual 1,42,857 52,14,281 Non-Promoter Public Public Medhora TOTAL 21,45,145 7,82,97,793 *The Proposed Allottees, namely Dhiren Chandulal Shah (“Acquirer 1”) and Sunil Chinubhai Shah (“Acquirer 2”) (hereinafter collectively referred to as the (“Acquirers”) along with Dhairya Dhiren Shah (“PAC 1”), Hiren Pravin Doshi (“PAC 2”), Sheetal Hiren Doshi (“PAC 3”), Nirmal Sunilbhai Shah (“PAC 4”), Rupa Sunil Shah (“PAC 5”), Vijaykumar Natvarlal Shiyani (“PAC 6”), Kamlesh Natvarlal Shiyani (“PAC 7”), Abhay Chinubhai Shah (“PAC 8”), shall, in accordance with Regulation 3(1) and Regulation 4 read with other applicable provisions of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended (“SEBI (SAST) Regulations”), trigger the open offer process. Upon completion of the open offer, the Acquirers and the PACs shall be classified as the Promoters and members of the Company. The shareholders are further informed and take note of the following changes in the Explanatory Statement to item no 3 and 4 to the Notice of EGM; (b) In point no XXVII following, be substituted and read as under; XXVII: Practicing Company Secretary’s Certificate The certificate from Shreyans Jain & Co. (Practicing Company Secretary), Membership No. (FCS: 8519) (COP No. 9801), pursuant to Regulation 163(2) of the LODR Regulations certifying that the Preferential Issue is being made in accordance with the requirements contained in the ICDR Regulations, shall be available for inspection by the members at the EGM and will also be made available on the Company’s website and can be accessed at https://parmaxpharma.com/files/PCS_CERTIFICATE_PPL_UR_163_PREFERENTIAL_ISSUE.pdf Additionally, the certificate will also be available for electronic inspection by the members during business hours. Members seeking to inspect such documents may send a request on the email ID: cs@parmaxpharma.com at least 1 (one) working day before the date on which they intend to inspect the document. The aforesaid correction is being made only to facilitate direct access to the PDF version of the Practicing Company Secretary's Certificate as required. There is no change in the contents, validity, conclusions, certifications or disclosures contained in the said certificate. All other contents of the Notice of EGM dated June 8, 2026 shall remain unchanged. This Corrigendum shall form an integral part of the Notice of EGM and the Notice shall be read in conjunction with this Corrigendum. Accordingly, all concerned stakeholders, members, depositories, registrar and share transfer agent, agencies appointed for e-voting, other authorities, regulators, and all other concerned persons are requested to take note of the above changes. This Corrigendum is also being sent onl [Showing first 8,000 characters — download PDF for full document]